We aimed to explore the clinical efficacy and effects of albuterol combined with tiotropium bromide on pulmonary functions of patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). 72 patients with AECOPD were divided into a combination treatment group (n = 38, albuterol + tiotropium bromide) and the control group (n = 34, routine treatment). Efficacy, incidence of adverse reactions, results of blood gas analysis, pulmonary function indices, time to improve clinical symptoms, St. George's respiratory questionnaire (SGRQ), and British Medical Research Council (MMRC) scores were compared between the two groups. The overall response rate was significantly higher, and the time to improve coughing was significantly shorter, in the combination treatment group compared with controls (p < 0.05). After treatment, both groups achieved a marked rise in PaO₂, forced expiratory volume in 1 s (FEV1), FEV1/forced vital capacity (FVC) ratio, and peak expiratory flow (PEF) (p < 0.05), which was more dominant with combination therapy. The reduction in PaCO₂ was more obvious in the combination therapy group. The combination of albuterol and tiotropium bromide is an effective treatment for patients with AECOPD and functions by improving conditions and pulmonary functions without raising the incidence of adverse reactions.

我们旨在探讨沙丁胺醇联合噻托溴铵对慢性阻塞性肺疾病（AECOPD）急性加重患者的肺功能的临床疗效和影响。将72例AECOPD患者分为联合治疗组（n  = 38，沙丁胺醇+噻托溴铵）和对照组（n = 34，常规治疗）。比较两组的疗效，不良反应发生率，血气分析结果，肺功能指数，改善临床症状的时间，圣乔治呼吸问卷（SGRQ）和英国医学研究理事会（MMRC）得分。与对照组相比，联合治疗组的总缓解率明显更高，并且改善咳嗽的时间显着缩短（p  <0.05）。治疗后，两组患者的PaO ₂，呼气量在1 s（FEV1），FEV1 /强迫肺活量（FVC）比率和呼气峰流量（PEF）均显着增加（p  <0.05）与联合疗法。PaCO ₂的减少在联合治疗组中更为明显。沙丁胺醇和噻托溴铵的组合通过改善病情和肺功能而不会增加不良反应的发生率，是对AECOPD患者和功能有效的治疗方法。